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Abstract Pro-MMP2 activation is a two-step process resulting
in (1) an intermediate 64 kDa form generated by the MT1-MMP
activity, and (2) a mature 62 kDa form. Addition of plasminogen
to HT1080 cells cultured under various conditions, or to their
membrane preparation, induced a complete conversion of the
intermediate MMP-2 form to the mature one, and processing of
pro-MMP-9. The pro-MMP-2 activation was inhibited by
plasmin inhibitors and anti-uPA antibody. These results provide
evidence for involvement of the PA/plasmin system in the second
step of MMP-2 activation.
z 1997 Federation of European Biochemical Societies.
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1. Introduction
MMP-2 (gelatinase A, collagenase type IV) is a member of
the matrixin enzyme family (MMP) [1]. By its ability to de-
grade type IV collagen, MMP-2 is believed to play a key role
in the basement membrane remodeling occurring during nor-
mal (embryonic development, tissue repair, angiogenesis) and
pathologic (metastasis) processes [2^4]. The pro-enzyme (72
kDa, pro-MMP-2) acquires its full proteolytic activity after
an activation step, which essentially involves removal of an
80-amino-acid residue N-terminus (the prodomain), resulting
in a lower molecular mass form (62 kDa) [5].
Increasing evidence is accumulating that, unlike the other
MMPs, pro-MMP-2 is activated via a membrane-associated
mechanism. We have previously shown that gelatinase A
binds to the cell surface of mammary carcinoma cells [6]. A
membrane type MMP (MT1-MMP) has been identi¢ed and
associated with pro-MMP-2 activation [7]. Three additional
membrane proteins (MT2-MMP, MT3-MMP and MT4-
MMP) have been reported and are probably involved in the
processing of progelatinase A [8^10]. The pro-MMP-2 activa-
tion is believed to involve two consecutive proteolytic cleav-
ages. The ¢rst one, associated with the MT1-MMP activity,
processes the pro-MMP-2 (72 kDa) to an intermediate form
(64 kDa) with amino-terminus Leu
67
[11,12]. The second one
generates the mature active form of MMP-2 and is supposed
to result from an autoproteolytic cleavage [13].
The involvement of plasminogen activator (PA)/plasmin
system in the activation of pro-MMP-2 has been a subject
of controversial interpretation. Keski-Oja et al. reported
that uPA is able to activate pro-MMP-2 [14]. Leupeptin and
its synthetic analogues inhibited pro-MMP-2 activation and
the in vitro migration of ¢brosarcoma cells [15]. On the con-
trary, Lim et al. demonstrated that, in HT1080 cell line,
MMP-2 and PA/plasmin system are di¡erentially regulated
and pro-MMP-2 activation is independent of serine proteases
[16].
In an attempt to better understand the possible role of the
PA/plasmin system in pro-MMP-2 activation, we used
HT1080 cells which express constitutively PA, MMP-2 and
MMP-9 [17,18]. Our results demonstrate that, although PA/
plasmin system cannot initiate pro-MMP-2 processing, it con-
verts totally the intermediate 64 kDa form of MMP-2 to a
mature, proteolytically active, 62 kDa form. Therefore, these
results suggest a cooperation between plasmin and MT1-
MMP in the activation process of pro-MMP-2.
2. Materials and methods
2.1. Cell culture
The human ¢brosarcoma HT1080 cells and human breast adeno-
carcinoma MCF7 cells were grown to 80% con£uence in Dulbecco's
modi¢ed Eagle medium (DMEM) supplemented with 10% foetal calf
serum, glutamine (292 mg/ml), sodium bicarbonate (2.1 g/l), ascorbic
acid (50 Wg/ml) and penicillin^streptomycin (100 U/ml). Cells were
seeded on plastic or type I collagen (20 ng/well)-coated 24-well plates.
Treatments with TPA (10 ng/ml), concanavalin A (ConA, 50 Wg/ml),
plasminogen (2^30 Wg/ml), aprotinin (5 Wg/ml) or TIMP-2 (100 nM)
were done under serum-free conditions. All chemicals were purchased
from Sigma (St. Louis, MO) and Gibco (Gaithersburg, MD). Human
plasminogen was puri¢ed by a¤nity chromatography on lysine^Se-
pharose [19]. Recombinant human MMP-2 produced from transfected
CHO cells was puri¢ed as previously described [20]. TIMP-2 was
produced by transformed Chinese hamster ovary cells (CHO) using
dihydrofolate reductase-methotrexate selection and ampli¢cation sys-
tem. TIMP-2 was puri¢ed from CHO-conditioned medium on Hitrap
Cu2

-chelating a¤nity column and Hitrap Q-column (Pharmacia Bio-
tech. Inc.) according to the procedure described by DeClerck et al.
[21].
2.2. Cell membranes preparations
Crude plasma membrane preparations were obtained as previously
described [22]. Essentially, cells were lysed with ice-cold bu¡er con-
sisting of 20 mM Tris-HCl, pH 7.6, 0.02% (w/v) Brij-35 and passed 10
times through a narrow-gauge needle. The whole-cell lysate was cen-
trifuged at 10 000Ug for 1 h at 4³C. The supernatant was retained and
centrifuged at 100 000Ug for 1 h at 4³C. The pellet was suspended in
bu¡er A, consisting of 50 mM Tris-HCl, pH 7.6, 0.2 M NaCl, 5 mM
CaCl
2
, 0.02% (w/v) Brij-35.
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Protein concentrations were determined by using the DC Protein
Assay Kit (Bio-Rad Laboratories, Hercules, CA) and adjusted to
2 mg/ml.
Aliquots of membrane preparation were incubated with recombi-
nant MMP-2 at 37³C for 16 h. The reaction was stopped by adding
non-reducing sample bu¡er for polyacrylamide gel electrophoresis.
Following centrifugation (12 000Ug, 15 min), samples were taken
for gelatin zymography.
2.3. Gelatin zymography
Media conditioned by cells (200 000 cells/well) were collected and
clari¢ed by centrifugation. Aliquots of conditioned media were stand-
ardized for cell DNA content [23], mixed with electrophoresis sample
bu¡er without reducing agent and applied without boiling to 10%
acrylamide gels containing gelatin 1 mg/ml. Gels were run at 20
mA, washed in 2% Triton X-100 for 1 h and incubated at 37³C for
16 h in activation bu¡er containing 50 mM Tris-HCl, pH 7.4, 0.2 M
NaCl, 5 mM CaCl
2
and 0.02% NaN
3
. In some experiments, the che-
lating agent EDTA (5 mM) or O-amino caproic acid (OACA, 100 mM)
were added to the activation bu¡er to prove the metalloproteinase or
serine proteinase nature of the gelatinolytic activities, respectively.
After staining with Coomassie brilliant blue R-250, the gelatinolytic
activities were detected as clear bands against the blue background.
Molecular weight standard proteins (Bio-Rad Laboratories, Hercules,
CA) were run simultaneously. The degree of digestion was estimated
by laser scanning densitometry using a model GS-700 Imaging Densi-
tometer (Bio-Rad, Richmond, CA) equipped with molecular Analyst
software.
2.4. Enzyme assay
MMP-2 activity was assayed using heat-denatured,
3
H-labelled type
I collagen as a substrate. The enzyme was ¢rst activated by incubation
with membrane preparation of HT1080 cells for 24 h in the presence
or absence of plasminogen. Thereafter, the radiolabelled substrate was
added. As a positive control of the enzymatic reaction, we used 1 mM
4-amino-phenylmercuric acetate (APMA)-activated MMP-2. As a
negative control, 10 mM EDTA was added to the incubation mixture.
2.5. Northern blot analysis
Con£uent HT1080 human ¢brosarcoma cell line was cultured for
24 h in serum-free DMEM. After removing conditioned media, cells
were washed extensively with PBS and RNAs were extracted as pre-
viously described [24]. From each experimental condition, 15 Wg of
RNA were separated by electrophoresis on a 1% agarose/formalde-
hyde gel and transferred to a nylon ¢lter (Hybond-N, Amersham) for
Northern blot hybridization. Filters were allowed to dry and RNAs
were ¢xed under UV light for 5 min. Prehybridization and hybrid-
ization were performed according to Maniatis et al. [25].
A cDNA probe for the MT1-MMP was designed by RT-PCR on
JAR cell poly A-RNA as template (American Type Collection no.
HTB144) as previously described [26]. The probe was labelled (aver-
age of 10
9
cpm/Wg DNA) with
32
P-deoxyribonucleotides by random
priming DNA labelling method according to the manufacturer (Boeh-
ringer-Mannheim). Filters were washed, dried and exposed to X-ray
¢lms. Uptake of radioactivity was determined by scanning the auto-
radiograms using an Ultroscan XL Laser Densitometer, LKB (Phar-
macia, Uppsala, Sweden). The relative amount of RNA loaded on the
gel was estimated from ethidium bromide staining.
3. Results
3.1. E¡ect of plasminogen on gelatinases activation by HT1080
cells cultured on plastic
When human ¢brosarcoma HT1080 cells were cultured on
plastic for 48 h, they secreted pro-MMP-9 (92 kDa), pro-
MMP-2 (72 kDa) and its intermediate form (64 kDa) (Fig.
1A, lane 1). We investigated the e¡ect of increasing concen-
trations of plasminogen on pro-MMP-9 and pro-MMP-2 ac-
tivation. After 48 h of incubation in the presence of plasmi-
nogen (5^30 Wg/ml), the gradual appearance of activated
MMP-9, in a concentration-dependent manner, was clearly
observed (Fig. 1A, lanes 3^6). Addition of plasminogen re-
sulted also in the conversion of the intermediate MMP-2 (64
kDa) into active MMP (62 kDa). The mature MMP-2 form
(62 kDa) was already identi¢ed in samples treated with low
concentration of plasminogen (2 Wg/ml) and its level was not
a¡ected by higher concentration of this serine protease. The
metalloproteinase nature of these gelatinolytic bands was as-
sessed by their inhibition by 10 mM EDTA (data not shown).
The conversion of inactive plasminogen to active plasmin by
HT1080 cells was veri¢ed by gelatin zymography performed,
in the absence or in the presence of O-ACA, on medium con-
ditioned by HT1080 cells treated with plasminogen for 24 h
(data not shown).
In order to con¢rm that the observed plasminogen e¡ects
on gelatinases activation could be ascribed to plasmin gener-
ated by cells, we treated HT1080 cells with increasing concen-
trations of plasmin (0.5^12 Wg/ml). Under these conditions,
the activation of pro-MMP-9 and the conversion of the inter-
mediate MMP-2 form into the mature (62 kDa) species were
similarly observed (Fig. 1B).
To rule out the possibility that active MMP-2 generated by
plasmin was involved in pro-MMP-9 processing, cells were
treated with di¡erent concentrations of plasminogen (5^30
Wg) and TIMP-2 (100 nM). Although, the level of activated
MMP-9 was increased in the presence of plasminogen, it was
not a¡ected by the addition of TIMP-2 (Fig. 2). On the con-
trary, TIMP-2 inhibited the spontaneous formation of inter-
mediate MMP-2 form (64 kDa) and consequently that of the
mature MMP-2 (Fig. 2, lanes 3,5,7, and 9). These results
con¢rm the involvement of MMP in the ¢rst step of pro-
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Fig. 1. Zymographic analysis of medium conditioned by HT1080
cells cultured on plastic and treated with increasing concentrations
of plasminogen (A) or plasmin (B). A: Cells were cultured in the
absence (lane 1) or presence of plasminogen: 2 Wg/ml (lane 2), 5 Wg/
ml (lane 3), 10 Wg/ml (lane 4), 20 Wg/ml (lane 5) and 30 Wg/ml (lane
6). B: Cells were cultured in the absence (lane 1) or presence of
plasmin: 0.5 Wg/ml (lane 2), 1 Wg/ml (lane 3), 2 Wg/ml (lane 4), 4 Wg/
ml (lane 5), 8 Wg/ml (lane 6), 12 Wg/ml (lane 7).
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MMP-2 activation. This MMP has previously been identi¢ed
as the MT1-MMP [7].
3.2. E¡ect of plasminogen on gelatinases activation by HT1080
cells treated with ConA, TPA or seeded on type I collagen
layer
We next focused our interest on the conversion of the in-
termediate MMP-2 form to the active MMP-2 by plasmin.
HT1080 cells were always treated with plasminogen at a con-
centration (2 Wg/ml) which did not a¡ect MMP-9 activation
but which in£uenced the second step of pro-MMP-2 activa-
tion. The cells were stimulated with ConA, TPA or seeded on
type I collagen layer, which are known to enhance gelatinase
A processing and expression of its membrane activator, the
MT1-MMP. Under these conditions, we con¢rmed an in-
creased expression of MT1-MMP mRNA by Northern blot
analysis (Fig. 3).
When HT1080 cells were cultured on plastic in the presence
of ConA or TPA, the appearance of the intermediate and
mature forms of MMP-2 in conditioned medium was ob-
served (Fig. 4, lanes 3 and 7, respectively). The addition of
plasminogen to these stimulated cells provoked total conver-
sion of the intermediate MMP-2 form to the mature one (Fig.
4, lanes 4 and 8, respectively). This process was inhibited by
aprotinin (Fig. 6, lanes 5 and 9, respectively), indicating that
the PA/plasmin system was implicated in the proteolytic cleav-
age of MMP-2 intermediate. Interestingly, TIMP-2 inhibited
the induction of the MMP-2 intermediate form (64 kDa) by
ConA (Fig. 4, lane 6) or TPA (data not shown). In the pres-
ence of TIMP-2, plasminogen had no e¡ect on the zymogen
(Fig. 4, lane 6) and was thus unable to initiate the pro-MMP-
2 processing.
We next cultured HT1080 cells on a type I collagen layer.
Under these culture conditions, the medium conditioned by
¢brosarcoma cells contained gelatinolytic activities corre-
sponding to pro-MMP-9, pro-MMP-2, and the two activated
forms of the latter (64 and 62 kDa) (Fig. 5, lane 1). The
addition of plasminogen induced the conversion of the inter-
mediate form to the mature one (Fig. 5, lane 2). The e¡ect of
ConA or TPA on MMP-2 activation was additive to that of
type I collagen (Fig. 5, lanes 3 and 7). Addition of plasmino-
gen induced total processing of the intermediate form (Fig. 5,
lanes 4 and 8). Aprotinin inhibited the conversion of the in-
termediate species to the mature MMP-2 form (Fig. 5, lanes 5
and 9), indicating again that this process was dependent on
the serine protease activity. In the presence of TIMP-2, the 72
kDa zymogen was the only MMP-2 form detected, thus con-
¢rming that the initial cleavage was metalloproteinase-de-
pendent (Fig. 5, lane 6).
3.3. E¡ect of plasminogen on gelatinases activation by
membranes of HT1080 cells
The involvement of plasminogen in MMP-2 processing was
further analysed by using membrane preparations of HT1080
cells incubated with recombinant pro-MMP-2. The membrane
preparation was able to process the pro-MMP-2 to its inter-
mediate and mature forms (Fig. 6, lane 2). This suggested that
the activator (MT1-MMP) was proteolytically functional and
generated the intermediate form. The activation ratio (62 kDa
form/72 kDa+64 kDa+62 kDa forms) was estimated by scan-
ning densitometry. In the presence of plasminogen, the inter-
mediate MMP-2 form was completely processed to the mature
one (Fig. 6, lane 3) and gave rise to an activation ratio of
0.239. Aprotinin, added to the incubation mixture, containing
the membrane preparation, pro-MMP-2 and plasminogen, in-
hibited the conversion of the intermediate MMP-2 to the ma-
ture form (activation ratio= 0.044), while a mAb against uPA
considerably slowed down this reaction (activation ratio=
0.074) (Fig. 6, lanes 4 and 5, respectively). These results
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Fig. 3. Northern blot analysis of HT1080 cells. Cells were cultured
on plastic (lane 1) and treated with TPA (lane 2), or ConA (lane 3)
or cultured on type I collagen layer (lane 4).
Fig. 2. E¡ect of TIMP-2 (100 nM) on the activation of pro-MMP-9
and pro-MMP-2 produced by HT1080 cells cultured on plastic.
Cells were treated according to the above indications. Concentra-
tions of plasminogen were: 5 Wg/ml (lanes 2 and 3); 10 Wg/ml (lanes
4 and 5); 20 Wg/ml (lanes 6 and 7); 30 Wg/ml (lanes 8 and 9).
Fig. 4. Zymographic analysis of medium conditioned by HT1080
cells stimulated with ConA or TPA, treated or not treated with
plasminogen (2 Wg/ml) for 24 h and in the presence of aprotinin or
TIMP-2 according to the above indications. The arrows on the right
indicate the proteolytic activity associated with plasmin.
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showed that the PA/plasmin system was involved in the proc-
essing of the intermediate MMP-2 form.
Additional con¢rmation for the implication of PA/plasmin
system only in the second step of pro-MMP-2 activation was
obtained with membrane preparation from MCF7 mammary
carcinoma cells. This cell line is characterized by a functional
PA/plasmin system [28] but it does not express MT1-MMP
mRNA. In the presence or absence of plasminogen, the mem-
brane preparation did not activate the pro-MMP-2 (Fig. 7,
lanes 2 and 3).
The pro-MMP-9 secreted in the medium conditioned by
HT1080 cells was activated in the presence of plasminogen,
by membranes of both MCF7 cells (Fig. 7, lane 4) and
HT1080 cells (data not shown), which is consistent with the
presence of a functional PA/plasmin system in both mem-
branes preparations.
In order to determine if the mature MMP-2 generated by
PA/plasmin system is proteolytically active, a quantitative en-
zymatic assay was carried out with
3
H-labelled gelatin sub-
strate (Fig. 8. The percentage of substrate degradation was
similar when we used pro-MMP-2 activated by APMA
(18þ 5%), membrane-activated pro-MMP-2 in the absence
(22þ 5%) or in the presence (21þ 3%) of plasminogen.
4. Discussion
The human ¢brosarcoma HT1080 cell line represents a suit-
able model for studying the cooperation between MMPs and
PA/plasmin system in the activation processes of gelatinases
(MMP-9 and MMP-2). Fibrosarcoma HT1080 cells are able
to activate exogenously added plasminogen to plasmin, as a
result of the membrane receptor bound uPA activity [17].
These cells also secrete both pro-MMP-9 and pro-MMP-2.
We studied the role of PA/plasmin system in the activation
of both pro-MMP-9 and pro-MMP-2.
HT1080 cell monolayers treated with plasminogen or plas-
min activated pro-MMP-9 in a concentration-dependent man-
ner. Studies with puri¢ed enzymes have shown the ability of
plasmin to activate pro-MMP-9 [29]. Fibroblast monolayers
treated with plasminogen activated exogenous pro-MMP-9
[30]. Our results con¢rm that plasmin can activate the endo-
genously secreted MMP-9. The activation mechanism of
MMP-9 is not elucidated, but it is considered to be a mem-
brane-independent process. This is supported by our ¢nding
that membrane preparations of MCF7 cells or HT1080 cells
were unable to activate pro-MMP-9 present in medium con-
ditioned by HT1080 cells. Under these conditions, addition of
plasmin or plasminogen is required in order to observe the
activation of pro-MMP-9. Pro-MMP-9 has been shown to be
activated by MMP-2 in vitro [31], and this process was inhib-
ited by TIMP-2. We demonstrate that TIMP-2 fails to a¡ect
the activation of pro-MMP-9 in the presence of plasminogen,
suggesting that the mature MMP-2 is unlikely involved in pro-
MMP-9 processing.
Membrane-pro-MMP-2 activation is thought to be a two-
step process: the ¢rst one involving MT1-MMP activity gen-
erates the intermediate form (64 kDa), and the second one,
due to an intermolecular autocatalytic reaction, results in the
formation of mature MMP-2 form. MT1-MMP is produced
by HT1080 cells and its level of expression can be modulated
by TPA, ConA and type I collagen. The cooperation between
MT1-MMP and plasma membrane generated plasmin in
MMP-2 activation has not yet been clearly documented. How-
ever, it has been shown that isolated extracellular matrices of
human ¢broblasts treated with uPA caused processing of ma-
trix-bound 72 kDa gelatinase to 64 and 62 kDa [14]. Leupep-
tin and a synthetic analogue suppressed in vitro invasion of
HT1080 cell line and MMP-2 activation [15]. These data are
in support of the implication of the serine protease system in
pro-MMP-2 processing.
We provide evidence that although the PA/plasmin system
cannot initiate pro-MMP-2 activation, it may be involved in
the second step of this reaction. This is supported by the
following observations. (1) The treatment of HT1080 cells
with plasminogen converted the intermediate MMP-2 form
to the mature one. (2) A similar e¡ect was observed by treat-
ment with plasmin. (3) The plasminogen treatment of cells
stimulated with ConA, TPA or type I collagen led to the total
conversion of the intermediate MMP-2 form to the mature
one; this process was inhibited by aprotinin and a monoclonal
antibody (mAb) raised against uPA.
ConA, TPA and type I collagen induced an enhancement of
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Fig. 5. Zymographic analysis of medium conditioned by HT1080
cells cultured on type I collagen layer. Cells were stimulated with
ConA or TPA, treated with plasminogen (2 Wg/ml), aprotinin or
TIMP-2 for 24 h according to the above indications. The arrow on
the right indicates the proteolytic activity associated with plasmin.
Fig. 6. Zymographic analysis of recombinant pro-MMP-2 incubated
with membranes of HT1080 cells. Lane 1: pro-MMP-2; lane 2:
pro-MMP-2 incubated with membrane preparation; lane 3: pro-
MMP-2 incubated with membrane preparation and plasminogen;
lane 4: pro-MMP-2 incubated with membrane preparation, plasmi-
nogen and aprotinin; lane 5: pro-MMP-2 incubated with membrane
preparation, plasminogen and a mAb against uPA; lane 6: mem-
brane preparation; lane 7: pro-MMP-2, activated with APMA, used
as a marker of the molecular mass of the intermediate and mature
MMP-2 forms. The arrows on the right indicate the proteolytic ac-
tivity associated with plasmin.
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pro-MMP-2 activation, resulting in the appearance of the in-
termediate, and mature forms of MMP-2 produced by di¡er-
ent cell types [11,27,32,33]. The HT1080 cells express consti-
tutively MT1-MMP and thus process spontaneously the pro-
MMP-2 to the intermediate form. In accordance with a pre-
vious work [13], we show that TIMP-2 inhibits the ¢rst step of
pro-MMP-2 activation and that addition of plasminogen in
the presence of TIMP-2 has no e¡ect on zymogen processing.
These results indicate that the serine protease system cannot
initiate pro-MMP-2 activation. The fact that relatively low
concentration of plasminogen induces total processing of the
intermediate MMP-2 form suggests that this interaction takes
place on the cell membrane, where MT1-MMP and the recep-
tor bound uPA colocalize. Therefore, we used membrane
preparations of HT1080 which were able to induce the ¢rst
step of pro-MMP-2 activation. In the presence of plasmino-
gen, the intermediate MMP-2 form was completely converted
to a mature one. This reaction was inhibited by aprotinin, and
a blocking mAb raised against uPA, indicating that the uPA/
plasmin system is involved in this reaction.
Con¢rmation of the role of plasmin in the second step of
pro-MMP-2 activation was obtained by using membrane
preparations of MCF7 human breast carcinoma cells. These
cells do not express MT1-MMP mRNA [34] and their mem-
branes were unable to activate the exogenously added pro-
MMP-2 to the intermediate form. Even in the presence of
plasminogen, the activation of pro-MMP-2 was not initiated.
However, the exogenously added pro-MMP-9 was activated,
thus suggesting that the membrane preparation generated
plasmin.
The mature MMP-2 form, generated by HT1080 membrane
preparation in the presence or absence of plasminogen, hydro-
lysed the
3
H-labelled substrate to the same extent, as did the
APMA activated pro-MMP-2. This indicates that plasmin
processed the intermediate form to a proteolytically active
¢nal species. However, we cannot exclude a stepwise activa-
tion mechanism, i.e. after the initial cleavage by MT1-MMP,
plasmin removes part of the propeptide domain by speci¢c
cleavage which is completed by autoproteolysis, thereby gen-
erating the mature MMP-2 form.
Altogether our data provide the ¢rst evidence for a coop-
eration between a membrane MMP and the PA/plasmin sys-
tem in the activation of pro-MMP-2. Although procollage-
nase-3 (MMP-13) was activated in vitro by MT1-MMP, the
addition of plasminogen to ConA stimulated ¢broblast mono-
layers had no e¡ect on the processing rate [35]. Thus, in this
cell system a physiological role for activation of MMP-13 by
plasmin was excluded. Therefore, the implication of uPA/plas-
min system in the activation of MMP-2 represents a new
activation cascade and may be of great importance in vivo.
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APMA, used as a marker for the molecular mass of the intermedi-
ate and mature MMP-2 forms. The arrows on the right indicate the
proteolytic activity associated with plasmin.
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